Experimental gene therapy shows promise against hydrocephalus
Researchers at the University of Cincinnati College of Medicine have published the first proof-of-concept study showing the potential of an experimental gene therapy for hydrocephalus. The preclinical research from the lab of Agnes (Yu) Luo was recently published in the journal Fluids and Barriers of the CNS, which focuses on specialized cerebrospinal fluid (CSF) biology.
Researchers at the University of Cincinnati College of Medicine have developed an experimental gene therapy for hydrocephalus, a condition where excess cerebrospinal fluid builds up in the brain, causing pressure and neurological impairment. Current treatments involve invasive brain surgery, which can fail and have technical and safety limitations.
The new gene therapy, delivered via an adeno-associated virus (AAV), targets and reduces cell types responsible for cerebrospinal fluid production, aiming to limit its spread into brain tissue. This approach could offer a less invasive and more comprehensive treatment option. Collaborating neurosurgery researchers at UC Davis induced hydrocephalus in adult animal models and successfully treated them with the experimental gene therapy, reducing brain tissue edema and cerebrospinal fluid production.
While the therapy also moderately decreased postnatal neurogenesis in the hippocampus, the main focus is on the significant reduction in fluid accumulation. Further research will explore the safety and efficacy of the AAV gene therapy in larger animal models and, eventually, human clinical trials to potentially provide a groundbreaking treatment for hydrocephalus.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
